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Kikuchi’s disease, or necrotizing histiocytic lymphadenitis, is a rare disease that presents
predominantly in young women in their 20s and 30s from the Far East. Our case depicts an
African-American male, in his sixth decade of life, presenting with Kikuchi’s disease, making
our case unusual. The clinical presentation, together with laboratory and pathological tests
described here, specifically the utilization of immunohistochemistry, aid in establishing a di-
agnosis. We advocate the use of steroids as symptomatic therapy and provide a novel and
successful therapeutic regimen. We do not recommend antibiotic therapy until an infectious
etiology is confirmed.
INTRODUCTION
Kikuchi’s disease, or necrotizing histi-
ocytic lymphadenitis, is a rare disease,
characterized by the presence of enlarged
and inflamed lymph nodes. Literature re-
views have estimated that up to 80 percent
of the patients are of Far Eastern descent,
with the disease showing a preponderance
toward women [1]. Only six of the 108 pa-
tients surveyed in a study of Kikuchi’s dis-
ease diagnosis wereAfrican-American and
showed an age range from 11 to 75 years
[1], while the typical age of presentation is
in the third to fourth decades of life. Our
patient, a 51-year-old African-American
male, is therefore unusual as a patient with
this disease.
The epidemiology of Kikuchi’s disease
is widespread, spanning the globe from
Japan, where it was first described in 1972,
to the United States, and including Europe,
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The first documented cases outside of Japan
were described by Pileri et al., depicting
cases in West Germany, Iran, Italy, Korea,
and Spain [6]. This was shortly followed by
the first cases reported in the United States
[1,7]. There has been no strong genetic pre-
disposition established for this disease. Rare
familial cases have been reported primarily
from Japan and SaudiArabia [2,5]. Here, we
report a case study of a 51-year-oldAfrican-
American male with Kikuchi’s disease and
describe a novel and successful tapered
steroidal therapeutic regime. Our patient had
no pertinent travel history. He was raised in
NewYork City and knew of no family mem-
ber who had an illness with symptoms sim-
ilar to his.
CASE HISTORY
A 51-year-old African-American male
presented to the emergency room with a his-
tory of intermittent fever, chills, poor ap-
petite, nausea, vomiting, and cough with
productive white sputum for the past 10
days. He also complained of progressively
worsening right-sided facial swelling, par-
ticularly around the parotid region, and se-
vere peri-orbital edema, all of which had
originated four weeks prior to presentation.
He had noticed a seven- to eight-pound
weight loss within those four weeks as well.
He worked in a homeless shelter as an ad-
ministrator. He was diagnosed and treated
for tuberculosis in 1985.
Upon physical examination, the patient
was febrile, 104.1°F, had significant peri-or-
bital edema, along with enlarged and tender
lymph nodes in the right parotid region, pre-
tragal area, and the anterior cervical region.
His laboratory results are given in Table 1,
revealing marked neutropenia and lym-
phopenia.
HOSPITAL COURSE
The patient was started on ceftriaxone
and azithromycin immediately upon admis-
sion, without improvement. On the second
admission day, his antibiotic regimen was
changed to ceftriaxone and clindamycin,
which the patient received for 15 days, but
he remained completely unresponsive to
therapy.Acomputed tomography (CT)† scan
of the head and neck on hospital day three
confirmed cervical lymphadenopathy, in-
flammation of the right parotid gland, and
peri-orbital edema (Figure 1). The patient
underwent fine needle aspiration (FNA) of
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Figure 1. Computed
tomography scan of
the neck in a patient
with Kikuchi's dis-
ease. Computed to-
mography scan of the
neck done on day 3,
depicting enlargement
and heterogeneous en-
hancement of the right
parotid gland.29 Mahmood et al.: Kikuchi’s disease
Table 1. Laboratory work-up results of a patient with Kikuchi’s disease (all abnormal
values are boldfaced).
Complete blood count Reference Range
White Blood Cells (K/uL) 1.7 4.8 - 10.8
PMN (%) 59.2 42.2 - 75.2
Lymphocytes (%) 33.6 20.5 - 51.1
Eosinophils (%) 0.1 0.0 - 7.0
Monocytes (%) 5.8 1.7 - 9.3
Platelets (K/uL) 189 130 - 400
Hemoglobin (g/dL) 12.4 14.0 - 18.0
Mean Corpuscular Volume (fL) 79.4 80.0 - 94.0
Sedimentation Rate (mm/Hr) 35 0 - 9
Basic metabolic profile
Sodium (mmol/L) 129 135 - 145
Potassium (mmol/L) 3.1 3.5 - 5.0
Chloride (mmol/L) 94 97 - 107
CO2 (mmol/L) 30 24 - 32
BUN (mg/dL) 8.0 8 - 22
Creatinine (mg/dL) 0.8 0.8 - 1.5
Glucose (mg/dL) 135 65 - 110
Liver function tests
Total bilirubin (mg/dL) 0.4 0.2 - 1.0
AST (alanine aminotransferase U/L) 117 7 - 40
ALT (aspartate aminotransferase U/L) 60 1 - 40
ALP (alkaline phosphatase U/L) 120 30 - 115
LDH (lactate dehydrogenase) 815 100 - 225
Protein, total (g/dL) 5.9 6.0 - 8.0
Albumin (g/dL) 3.0 3.5 - 5.0
Hepatitis C antibody Positive Negative
Hepatitis screening Hepatitis A & B Negative
Negative
C3 complement (mg/dL) 160.0 76.0 - 181.0
C4 complement (mg/dL) 50.7 12.0 - 52.4
ANA Screen Negative Negative
Anti-dsDNA Negative Negative
Rheumatoid factor (IU/mL) 25.0 0.0 - 11.0
HIV Negative Negative
HTLV - I/II Non-reactive Non-reactive
CMV AB, IGM (ISR) 2.34 0.0 - 0.9
CMV AB, IGG (ISR) 0.64 0.0 - 0.9
EBV Capsid AB, IGM (ISR) 0.0 0.0 - 0.9
EBV Capsid AB, IGG (ISR) 2.16 0.0 - 0.9
EBV EAAB IgG (strength of signal) 1.34 Neg: 0 - 0.9
Equivocl:0.91 - 1.09
Pos: > 1.1
All blood cultures Negative Negative
All bone marrow cultures Negative Negativethe parotid gland on day nine, which re-
vealed mild acute and chronic inflammation
of salivary acinar units and duct epithelium.
An excisional lymph node biopsy was per-
formed on day 10. Ceftriaxone and clin-
damycin were discontinued on day 16. He
had his final fever spike on day 20. A gal-
lium scan on day 22 showed infection/in-
flammation of the right parotid gland, and
he was started on intravenous methylpred-
nisolone-succinate 60 mg every 12 hours on
day 22. His condition improved, the peri-or-
bital swelling decreased, and he remained
afebrile. The patient was started on oral
steroids — prednisone 40 mg per day — on
hospital day 24 and was discharged the fol-
lowing day, with a tapered regimen of oral
steroids to complete his treatment: pred-
nisone 40 mg daily for three days, 30 mg
daily for three days, 20 mg daily for three
days, and 10 mg for one day. The patient re-
turned to the emergency room two weeks
following discharge, suffering from symp-
toms of Clostridium difficile colitis.
RADIOGRAPHIC FINDINGS
The contrast-enhanced CT scan of the
neck revealed enlargement and heteroge-
neous enhancement of the right parotid
gland (Figure 1). Multiple cervical lymph
nodes were also noted.These were less than
15 millimeters in size and were uniform in
attenuation.
PATHOLOGICAL FINDINGS
The lymph node architecture was exten-
sively effaced by diffuse necrosis that was
predominantly paracortical and spared occa-
sional reactive follicles. Necrotic areas con-
tained apoptotic bodies and were surrounded
by a cellular proliferation, which included
variable proportions of round, pale cells
with blastic morphology consistent with
plasmacytoid monocytes, transformed lym-
phocytes, and predominant histiocytes, often
with crescentic nuclei. Neutrophils were ab-
sent.
Immunophenotyping disclosed that the
cellssurrounding necroticareasweremainly
activated T-cells, expressing either CD4 or
CD8 antigen, and some small CD20 positive
B-cells. The immunostain with HECA-452
(directed againstcutaneouslymphocyteanti-
gen)highlightednumeroustransformedlym-
phocytes and plasmacytoid monocytes. The
latter, along with many macrophages, also
expressed PG-M1 (against macrophage-re-
strictedCD68epitope)(Figure2).Withinthe
remaininglymphoidareas,CD20positiveB-
cells and CD3 positive T-cells were distrib-
uted as expected in reactive lymphoid tissue.
A PCR from extracted DNA for im-
munoglobulin heavy-chain andT-cell recep-
tor gamma chain gene rearrangements failed
to reveal a monoclonal cell population. In
situ hybridization for Epstein-Barr virus-en-
coded RNAwas negative.
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Figure 2. Immunore-
activity used in




for HECA-452 in plas-
macytoid monocytes.
B. Immunoreactivity
for PG-M1 (an epit-
ome of CD-68) in
plasmacytoid mono-
cytes (immunohisto-
chemistry).The histological findings, together with
the immunologic and molecular studies,
supported a reactive lymphoid process con-
sistent with the diagnosis of necrotizing his-
tiocytic lymphadenitis (Kikuchi’s disease).
DISCUSSION
The etiology of Kikuchi’s disease is not
entirely known. It has been linked to sequela
of infection by human herpes virus 6, cy-
tomegalovirus (CMV), and even human T-
lymphotropic virus 1 [8-11]. Recent reports
had suggested links between Kikuchi’s dis-
ease and HHV-8 or Epstein-Barr virus
(EBV). These, however were discredited by
George et al. [12]. Some case reports have
linked Kikuchi’s disease to systemic lupus
erythematosus (SLE) as well, as patients
who attributed their symptoms to Kikuchi’s
disease went on to develop SLE. This miti-
gates the hypothesis that Kikuchi’s disease
may be an autoimmune disease. Serologic
tests confirmed that our patient was not in-
fected by any of these pathogens. Although
his EBV capsid antibody titers were above
the normal limit, signifying a past infection,
the in situ hybridization for EBV-encoded
RNAwas negative, indicating he was not ac-
tively infected.
The clinical presentation of Kikuchi’s
disease is very similar to malignant lym-
phoma, tuberculosis, and systemic lupus
erythematosus [13-16]. Laboratory analysis
revealed leukopenia and lymphopenia with-
out eosinophilia or basophilia. Elevated ery-
throcyte sedimentation rate, C reactive
protein, and serum lactate dehydrogenase
and transaminases were observed [17]
(Table 1). He had had a prior infection with
tuberculosis, his sputum was repeatedly cul-
tured for acid-fast bacilli and was negative,
and he had no evidence of SLE.
The pathologic hallmark of Kikuchi’s
disease is the presence of an enlarged lymph
node with paracortical necrotic foci, which
are devoid of neutrophils and surrounded by
plasmacytoid monocytes, immunoblasts and
crescentic histiocytes. Immunohistochem-
istry was helpful in identifying characteristic
plasmacytoid monocytes. The latter are non-
phagocytic natural type 1 interferon, produc-
ing cells more likely involved in cytotoxic
immune reactions. Recent studies using
CD68 and HECA-452 antibodies, on paraf-
fin-embedded sections, revealed that these
antibodies, together with CD4, marked the
plasmacytoid monocytes [5,18]. This co-ex-
pression of CD68 (PG-M1) and HECA-452
intheplasmacytoidmonocyteshasbeenpre-
viously reported in Kikuchi’s disease.
These histological findings are suffi-
ciently distinctive to permit an accurate di-
agnosis of Kikuchi’s disease, provided
systemic lupus erythematosus has been ex-
cluded by the appropriate serologic tests.
Malignant lymphoma, especiallyT-cell non-
Hodgkins lymphoma, can be mistaken for
Kikuchi’s disease. Loss of pan T-cell anti-
gens by immunostains and determination of
the monoclonality of T cells by molecular
studies are necessary for confirming the di-
agnosis of T-cell lymphoma.
It is possible to use fine needle aspira-
tion cytology (FNAC) to confirm the diag-
nosis of Kikuchi’s disease, but the focal
involvementcanbecompletelymissed,asil-
lustrated by the equivocal FNAC in our pa-
tient. Excisional biopsy eventually was
undertaken in our case, which consisted of
obtaining diagnostic tissue and a representa-
tive picture of its architecture, along with re-
moval of the swollen mass or masses.
Cross-sectional imaging findings in pa-
tients with Kikuchi disease have been de-
scribed as the presence of clusters of many
small or mildly enlarged lymph nodes that
appeared abnormal, mostly not because of
their size but because of the increased num-
ber. On CTand MR examination, the lymph
nodes were uniform in attenuation and in-
tensity. The cervical lymph nodes are com-
monly involved, but supraclavicular,
axillary, mediastinal, celiac, peripancreatic,
and inguinal chain lymph nodes have been
reported. The abnormality of the right
parotid region in our patient can be attrib-
uted to inflammation of the right parotid
lymph nodes.
The course of Kikuchi’s disease is rela-
tively benign and self limited [8,19,20].
Nevertheless, many therapeutic regimens
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course by reducing swelling and fever
spikes.The swelling in our patient was clin-
ically noteworthy, particularly in the right
peri-orbital region, where he was unable to
open his eye. While we do not advocate the
use of any therapy to treat Kikuchi’s disease,
steroid therapy is recommended by some to
alleviate the related symptoms, such as the
marked swelling. Steroid therapy, particu-
larly prednisone, can benefit patients suffer-
ing from symptoms such as severe edema
and fever, although our patient became
afebrile two days prior to the start of his
steroid regimen [3,21]. One case report de-
scribed the use of chloroquine to alleviate
symptoms over a five-month period [2].An-
other case study described the use of
minocycline, which alleviated symptoms in
10 days, encouraging the idea that this dis-
ease might be the result of microorganism,
rather than an autoimmune etiology [22].
These, however, were the results of single
case reports with no follow-up studies to our
knowledge.We discourage antibiotic use for
Kikuchi’s disease, particularly as no
causative microorganism has been identified
and the detrimental side effects these regi-
mens can have, as witnessed in our patient.
We encourage the use of a tapered steroid
regimen, as it was efficacious and of short
duration. Our patient was placed on a
steroidal regimen, previously described, and
responded dramatically with complete alle-
viation of the peri-orbital swelling within
two weeks; the patient also maintained his
afebrile state throughout the entire course.
The proposed steroid therapy with a dosage
regimen is unique to our knowledge in the
realm of Kikuchi’s disease management.
Our case report reinforces the idea that
although Kikuchi’s disease does predomi-
nantly affect young women, it can appear at
all ages, irrespective of gender.The constel-
lation of clinical findings consisting of re-
gional lymphadenopathy, fever, marked
leukopenia in the presence of characteristic
histiocytic necrotizing lymphadenitis, and
pathological analysis provide the diagnosis.
Although many treatment regimens have
been recommended, there has not been any
established therapy for this disease, nor have
any therapeutic trials been undertaken to our
knowledge.
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